Leadership

Dr. Werner Cautreels is a highly accomplished biopharmaceutical executive with a core emphasis in research and development in various therapeutic areas, who brings a deep understanding of clinical and regulatory strategy. During his 40-year plus career, his work has touched on psychiatry and neurology, cardiovascular, autoimmune, oncology, rare disease, and vaccines. Dr. Cautreels was President and CEO of Selecta Biosciences from July 2010 until 2018. Prior to Selecta Biosciences, Dr. Cautreels served as Global CEO of Solvay Pharmaceuticals until it was acquired by Abbott Laboratories in 2010. Prior to joining Solvay, he worked at Sanofi, Sterling Winthrop and Nycomed-Amersham in a variety of research and development management positions in Europe and the United States since 1987. Dr. Cautreels was also a Director of Innogenetics NV (Gent, Belgium) and of Arqule Inc. (Woburn, Massachusetts). Until April 2019, Dr. Cautreels was Director and Chair of the Audit Committee of Galapagos NV (Mechelen, Belgium). Dr. Cautreels currently serves on the board of directors of Third Pole Therapeutics, a privately held company developing critical life-sustaining therapies for people living with cardiopulmonary and infectious diseases, and on the advisory board of Thuja Capital, an early-stage venture capital firm. Dr. Cautreels also currently serves as CEO of Cristal Therapeutics (Maastricht, The Netherlands) and Chairman of MRM Health (Gent, Belgium). Dr. Cautreels has a Ph.D. in chemistry from the University of Antwerp, Belgium, and an Executive M.B.A. from Harvard Business School.

Dr. Pauza received the Ph.D. in Molecular Biology from the University of California, Berkeley and was a postdoctoral fellow in the laboratory of Sydney Brenner, M.D., Medical Research Council Laboratory of Molecular Biology in Cambridge, England. He held faculty positions at the Salk Institute for Biological Studies, La Jolla, CA, University of Wisconsin-Madison, University of Maryland Biotechnology Institute and University of Maryland, Baltimore School of Medicine where he served as Associate Director for the Institute of Human Virology and Co-Leader for the Viral Oncology Program in the Greenebaum Cancer Center. From 2016 to 2021 Dr. Pauza was Chief Science Officer for American Gene Technologies where he developed a cell and gene therapy for HIV and initiated Phase 1 studies of that product. He joined Viriom, Inc. as Chief Science Officer in 2017 and in 2021, became Chief Science Officer of Trawsfynydd Therapeutics, Inc. until it was acquired by Onconova Therapeutics in a deal that created Traws Pharma, where Dr. Pauza serves as Chief Science Officer, Virology. He holds more than 30 US patents and has more than 200 original publications in the fields of virology and cancer. Dr. Pauza is an active reviewer for many scientific journals and serves as grant reviewer for the U.S. National Institutes of Health in addition to national grant programs from 7 countries. He is actively involved in developing international scientific programs in West Africa, Europe, Russia and China, and was appointed in 2000 as the United Nations Education, Scientific and Cultural Organization Professor of Biotechnology, a position served in Rome, Italy.

Mr. Guerin joined Onconova Therapeutics in September 2013 to augment the financial reporting, forecasting, and internal controls capabilities of the company following the IPO in July 2013. He was promoted to Chief Operating Officer and CFO in June 2022. Prior to joining Onconova, Mr. Guerin worked as an interim senior finance & accounting executive facilitating the post-acquisition integration activities of newly acquired private equity portfolio companies.

Previously, Mr. Guerin was the VP Finance & CFO of Cardiokine, Inc. through that company’s filing of a New Drug Application and the sale of the company. Prior to joining Cardiokine, Mr. Guerin was Director, Financial Reporting & Internal Controls at Barrier Therapeutics, Inc. during Barrier’s IPO and follow-on offering. Mr. Guerin started his career at Coopers & Lybrand in Philadelphia. He received his bachelor’s degree in Accounting from DeSales University and has earned the CPA, CMA, and CFM professional certifications.

Dr. Redfield is a virologist and former director of the US Centers for Disease Control and Prevention (CDC) and the administrator of the Agency for Toxic Substances and Disease Registry from 2018 to 2021 and the senior public health advisor to Governor Hogan and the State of Maryland 2021-2023. He also served as a member of the White House Coronavirus Task Force and member of the board of Operation Warp Spread. He was a member of the US President’s Advisory Council on HIV/AIDS from 2005 to 2009 and was appointed as chair of the International Subcommittee from 2006 to 2009. He is a past member of the Office of AIDS Research Advisory Council at the National Institutes of Health, the Fogarty International Center Advisory Board at the National Institutes of Health, and the Advisory Anti-Infective Agent Committee of the Food and Drug Administration (FDA). Dr. Redfield is a co-founder of the Institute of Human Virology at the University of Maryland, School of Medicine. He has more than 35 years in experience in antiviral drug and vaccine development and is known for his contributions in clinical research into the virology and therapeutic treatments of HIV infection and other viruses. He also served as the Chief of Infectious Disease, Vice Chair of Medicine and Professor of Medicine, Immunology and Microbiology at the University of Maryland. He served in the US Army from 1977-1996 as a physician and medical researcher and retired as a Colonel in 1996.

Dr. Victor Moyo joined Onconova Therapeutics in June 2023 as Consulting Chief Medical Officer and transitioned to Chief Medical Officer in October 2023. Dr. Moyo is a highly experienced physician researcher and drug developer, with approximately 30 years of clinical research experience including 18 years in the pharmaceutical industry. He has held a variety of senior leadership positions with responsibility for a number of clinical development plans, IND filings, NDA filings, post-market development plans, notably including his work on such programs as Onivyde® for metastatic pancreatic cancer, epoetin alpha trial in myelodysplastic syndrome and the Doxil® trial in advanced ovarian cancer among others. He is also a named inventor on numerous granted patents and patent applications.

Most recently Dr. Moyo has been serving as Chief Medical Officer (CMO) of OncoPep, Inc. and Executive Vice-President, CMO and Head of R&D at L.E.A.F. Pharmaceuticals. Prior to that, he held various leadership roles as a Vice President Clinical Investigations or Medical Director at Merrimack Pharmaceuticals and the Centocor Ortho Biotech Services, LLC division of Johnson & Johnson.

Dr. Moyo earned his M.D. from the University of Zimbabwe. Following his move to the U.S., he went on to complete his internship and residency in Internal Medicine at the George Washington School of Medicine and Health Sciences and his fellowship in Hematology and Oncology at the Johns Hopkins University School of Medicine.

Dr. Savchuk is the co-founder and Managing Member at Torrey Pines Investment LLC, a life-science investment company, since 2002. Dr. Savchuk is also the Managing General Partner of Teal Ventures, LP, a venture capital firm focused on early-stage investing in health technology, since October 2018. Prior to joining life science investment and research in the United States, Dr. Savchuk was a fond of and held various business and research management positions in the IT industry with companies in Singapore and Russia. Dr. Savchuk is currently the chairman of the board of directors of Viriom Inc., a company dedicated to advancing a pipeline of effective and affordable treatments for diseases of global interest. Dr. Savchuk obtained his M.S. degree in physics and his Ph.D. in applied mathematics from Moscow Institute of Physics and Technology.